IP Library Granted Patent US 10,561,727
Granted Patent B2
US 10,561,727 · App. 15/520,623 · Granted Feb 18, 2020

Anti human Gas6 monoclonal antibody

Inventors: Yuko Ube (Tokyo, JP); Tsuyoshi Yamada (Tokyo, JP); Yuji Yamazaki (Tokyo, JP); Kaname Kimura (Tokyo, JP); Akiko Hariguchi (Tokyo, JP); Shinya Ogawa (Tokyo, JP)
Assignee: Kyowa Kirin Co., Ltd.
A61K39/3955A61K39/39558
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,561,727
App. No.
15/520,623
Granted
Feb 18, 2020
Kind
B2
Abstract

The present invention relates to an antibody specifically binding to human growth arrest specific 6 (hGas6). Specifically, the present invention relates to a monoclonal antibody or an antibody fragment thereof which binds to at least one of amino acid residues at positions 314, 315, and 316 of human Gas6, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment, a transformed cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment, a reagent for detection or assay of Gas6, comprising the antibody or the antibody fragment, a therapeutic agent or a diagnostic agent for a Gas6-related disease, comprising the antibody or the antibody fragment as an active ingredient, and use of the antibody or the antibody fragment for the production of a therapeutic agent or a diagnostic agent for a Gas6-related disease.

Claims (11)

1. A monoclonal antibody or an antibody fragment thereof which binds to at least one of amino acid residues at positions 314, 315, and 316 in the amino acid sequence of human Gas6 shown in SEQ ID NO: 4, wherein the monoclonal antibody is

an antibody in which the amino acid sequences of heavy chain (hereinafter, abbreviated to H chain) variable region (hereinafter, abbreviated to VH) complementarity determining region (hereinafter, abbreviated to CDR) 1 to CDR3 are the amino acid sequences shown in SEQ ID NOs: 79, 80, and 81, respectively, and the amino acid sequences of light chain (hereinafter, abbreviated to L chain) variable region (hereinafter, abbreviated to VL) CDR1 to CDR3 are the amino acid sequences shown in SEQ ID NOs: 82, 83, and 84, respectively.

2. The monoclonal antibody or the antibody fragment thereof according to claim 1 , wherein the monoclonal antibody is any one antibody selected from the following antibodies (a) and (b):

(a) an antibody in which the amino acid sequence of VH is the amino acid sequence shown in SEQ ID NO: 69, and the amino acid sequence of VL is the amino acid sequence shown in SEQ ID NO: 72;

(b) an antibody in which the amino acid sequence of VH is the amino acid sequence shown in SEQ ID NO: 135, and the amino acid sequence of VL is the amino acid sequence shown in SEQ ID NO: 123.

3. The monoclonal antibody or the antibody fragment thereof according to claim 1 , wherein the monoclonal antibody is a recombinant antibody.

4. The monoclonal antibody or the antibody fragment thereof according to claim 3 , wherein the recombinant antibody is a recombinant antibody selected from a human chimeric antibody, and a humanized antibody.

5. The monoclonal antibody or the antibody fragment according to claim 1 , wherein the monoclonal antibody or the antibody fragment is selected from Fab, Fab′, F(ab′) 2 , single chain Fv (scFv), diabody, and disulfide-stabilized Fv (dsFv).

6. A reagent for detection or assay of Gash, comprising the antibody or the antibody fragment thereof according to claim 1 and an agent to label the antibody.

7. A therapeutic agent comprising the antibody or the antibody fragment thereof according to claim 1 as an active ingredient and one or more pharmaceutically acceptable carriers.

8. A diagnostic agent comprising the antibody or the antibody fragment thereof according to claim 1 as an active ingredient and a reagent for detecting antigen-antibody reaction.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT CONVEYANCE TYPE FROM MERGER TO CHANGE OF NAME PREVIOUSLY RECORDED AT REEL: 050078 FRAME: 0503. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 21, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 051604/0903 →
MERGER Recorded Aug 16, 2019
From: KYOWA HAKKO KIRIN CO., LTD.
To: KYOWA KIRIN CO., LTD.
Reel/Frame 050078/0503 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2017
From: UBE, YUKO; YAMADA, TSUYOSHI; YAMAZAKI, YUJI; KIMURA, KANAME; HARIGUCHI, AKIKO; OGAWA, SHINYA
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 043611/0120 →
Continuity (2)
Provisional Application 62066687 · Oct 21, 2014
Related Publication 20180339041A1 · Nov 29, 2018